Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: Results of a multicentre, double-blind study (the amisulpride study group)

European Psychiatry

Volumn 15, Issue 5, 2000, Pages 321-329

  Carriere P ^a   Bonhomme, D ^b   Lemperiere T ^c  

^a Service Médico Psychologique Régional   (France)

^b SANOFI   (France)

^c NONE   (France)

Author keywords

Amisulpride; Antipsychotic; Atypical antipsychotic; Haloperidol; Schizophrenia

Indexed keywords

AMISULPRIDE; DOPAMINE RECEPTOR; FLUPENTIXOL; HALOPERIDOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RECEPTOR BINDING; SCHIZOPHRENIA; SOCIAL ADAPTATION;

EID: 0033888026     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(00)00401-6     Document Type: Article

References (37)

1. Practice guideline for the treatment of patients with schizophrenia
2. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
3. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
4. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
5. Motor and mental aspects of extrapyramidal syndromes
6. Evaluation de l'efficacite et de la tolerance de l'amisulpride dans le traitement des psychoses schizophreniques
7. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
8. Utility analysis of risperidone cost effectiveness
9. Drugs in the treatment of psychosis: Controlled studies
10. Measuring outcome in schizophrenia Differences among the atypical antipsychotics
11. Evaluating the effects of antipsychotics on cognition in schizophrenia
12. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
13. Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics
14. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride
15. Formulary decisions and health economics
16. The quality of life scale: An instrument for rating the schizophrenic deficit syndrome
17. A Comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia
18. The functional status questionnaire: Reliability and validity when used in primary care
19. The positive-negative dimension in schizophrenia: Its validity and significance
20. The positive and negative syndrome scale (PANSS) for schizophrenia
21. Risperidone in the treatment of schizophrenia
22. Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperidol
23. The Brief Psychiatric Rating Scale
24. Psychopharmacological profile of amisulpride: An antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity
25. Amisulpride vs risperidone in the treatment of acute exacerbations of schizophrenia
26. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs. haloperidol
27. Dosage of haloperidol for schizophrenia
28. Amisulpride: From animal pharmacology to therapeutic action
29. 3 receptor antagonist with both presynaptic and limbic selectivity
30. A rating scale for extrapyramidal side effects
31. Quetiapine in patients with schizophrenia
32. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
33. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia
34. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients
35. Amisulpride versus flupenthixol in schizophrenia with predominantly positive symptomatology - A double-blind controlled study comparing a selective D2-like antagonist to a mixed D1/D2-like antagonist
36. Controlled dose-response study of sertindole and haloperidol in the treatment of schizophrenia